Nanosphere, Inc.

Nanosphere to Release Q4 and Full Year 2012 Results and Hold Investor Call on Wednesday, February 13

NORTHBROOK, Ill., Feb. 5, 2013 (GLOBE NEWSWIRE) -- Nanosphere, Inc., (Nasdaq:NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, will report its results for the fourth quarter and full year after the market close on Wednesday, February 13, 2013. The company will also hold a live investor conference call and webcast at 5:00 P.M., Eastern Time.

Nanosphere, Inc.

Nanosphere Receives FDA Clearance for C. difficile Test

NORTHBROOK, Ill., Dec. 10, 2012 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (Nasdaq:NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, announced today the U.S. Food and Drug Administration (FDA) granted 510(k) clearance permitting marketing of its

Nanosphere, Inc.

Nanosphere to Present at Canaccord Genuity Medical Technology & Diagnostics Forum

NORTHBROOK, Ill., Nov. 29, 2012 (GLOBE NEWSWIRE) -- Nanosphere, Inc., (Nasdaq:NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, announced that William Moffitt, Nanosphere's president and chief executive officer, will present at the Canaccord Genuity Medical Technology & Diagnostics Forum taking place at the Le Parker Meridien Hotel in New York City on Tuesday, December 4, 2012 at 1:30 p.m. ET.

Nanosphere, Inc.

Nanosphere to Present at Piper Jaffray 24th Annual Healthcare Conference

NORTHBROOK, Ill., Nov. 21, 2012 (GLOBE NEWSWIRE) -- Nanosphere, Inc., (Nasdaq:NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, announced that William Moffitt, Nanosphere's president and chief executive officer, will present at the Piper Jaffray 24

Nanosphere, Inc.

Nanosphere Receives FDA Clearance to Market Test for Detection of CYP2C19 Mutations Affecting Drug Metabolism

NORTHBROOK, Ill., Nov. 13, 2012 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (Nasdaq:NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, announced today the US Food and Drug Administration (FDA) granted 510(k) clearance permitting marketing of its CYP2C19 Nucleic Acid Test (CYP2C19 Test) on the automated sample-to-result Verigene

Nanosphere, Inc.

Nanosphere Announces Third Quarter 2012 Results

NORTHBROOK, Ill., Nov. 7, 2012 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (Nasdaq:NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, today reported financial results for the third quarter ending September 30, 2012.

Nanosphere, Inc.

Nanosphere to Present at Lazard Capital Markets and Stephens Inc. Investor Conferences

NORTHBROOK, Ill., Nov. 6, 2012 (GLOBE NEWSWIRE) -- Nanosphere, Inc., (Nasdaq:NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, announced that William Moffitt, Nanosphere's President and Chief Executive Officer, will present at the following investor conferences in New York City:

Nanosphere, Inc.

Nanosphere's Bloodstream Infection Test Designated Moderate Complexity by FDA

NORTHBROOK, Ill., Nov. 1, 2012 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (Nasdaq:NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, announced today that it received notice from the U.S. Food and Drug Administration (FDA) that its Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) on the Verigene

Nanosphere, Inc.

Nanosphere to Release Q3 2012 Results and Hold Investor Call on Wednesday, November 7

NORTHBROOK, Ill., Oct. 26, 2012 (GLOBE NEWSWIRE) -- Nanosphere, Inc., (Nasdaq:NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, will report its results for the third quarter 2012 after the market close on Wednesday, November 7, 2012. The company will also hold a live investor conference call and webcast at 5:00 P.M., Eastern Time.

Nanosphere, Inc.

Nanosphere Test Accurately Detects a Broad Panel of Bacterial Targets and Resistance Determinants Directly From Blood Culture

NORTHBROOK, Ill., Oct. 22, 2012 (GLOBE NEWSWIRE) -- Nanosphere's (Nasdaq:NSPH) Verigene Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) (IUO), based on the company's proprietary array-based nanoparticle technology, demonstrated overall sensitivity and specificity of 99%, respectively, for the detection of a broad panel of gram-positive bacteria from positive blood cultures, according to a recent study. The BC-GP Test also correctly detected the presence or absence of genes encoding vancomycin resistance in